PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

doi:10.3748/wjg.v27.i25.3863

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 25

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5989)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

346

WORD

159

HTML

2996

Figures (1-1)

292

Tables (1-7)

502

Sum=4295

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

476

Download

1218

Sum=1694

Jul 7, 2021 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jul 7, 2021; 27(25): 3863-3876
Published online Jul 7, 2021. doi: 10.3748/wjg.v27.i25.3863

Table 1 Clinical characteristics of patients with nonalcoholic fatty liver disease and controls

Variables	NAFLD (n = 59)	Controls (n = 93)	P value
Sex (M/F)	43/16	59/34	0.227
Age (year)	38.20 ± 13.78	42.20 ± 11.05	0.039
BMI (kg/m²)	27.31 ± 3.31	23.06 ± 2.74	< 0.0001
ALT (U/L)	70.56 ± 47.6	24.98 ± 16.07	< 0.0001
GGT (U/L)	72.75 ± 55.22	25.94 ± 18.17	< 0.0001
ALP (U/L)	97.07 ± 44.73	96.50 ± 32.54	0.347
TC (mmol/L)	4.86 ± 0.86	4.39 ± 0.89	0.001
TG (mmol/L)	1.99 ± 1.25	1.14 ± 0.74	< 0.0001
HDL-C (mmol/L)	1.20 ± 0.28	1.23 ± 0.28	0.177
LDL-C (mmol/L)	2.83 ± 0.7	2.24 ± 0.50	< 0.0001
FBG (mmol/L)	5.93 ± 2.62	5.31 ± 0.79	0.941
UA (μmol/L)	361.32 ± 105.78	274.25 ± 76.53	< 0.0001
CAP (dB/m)	313 (277-351)	212 (172-232)	< 0.0001
LSM (kPa)	7.7 (5.6-12)	5.25 (4.1-7.0)	< 0.0001
Hypertension, n (%)	22 (37.29%)	15 (16.13%)	0.003
T2DM, n (%)	7 (11.86%)	1 (1.08%)	0.005
Obesity, n (%)	41 (69.49%)	19 (20.43%)	< 0.0001
Steatosis (S, n)
S1/S2/S3	25/25/9	/	/
Activity (A, n)
A0/A1/A2/A3/A4	1/12/16/22/8	/	/
Fibrosis (F, n)
F0/F1/F2/F3/F4	11/29/8/7/4	/	/

The data are expressed as mean ± SD, or as n (%) for normally distributed variables and as median (interquartile range) when distribution of the variable was skewed. NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; FBG: Fasting blood glucose; UA: Uric acid; LSM: Liver stiffness measurement; CAP: Controlled attenuation parameter; T2DM: Type 2 diabetes mellitus.

Table 2 Clinical characteristics of patients with nonalcoholic steatohepatitis and nonalcoholic fatty liver among patients with nonalcoholic fatty liver disease

Variable	NAFL (n = 22)	NASH (n = 37)	P value
Sex (M/F)	17/5	26/11	0.559
Age (year)	37.23 ± 13.64	38.78 ± 14.01	0.605
BMI (kg/m²)	27.07 ± 3.69	27.38 ± 3.17	0.675
ALP (U/L)	102.96 ± 52.34	93.56 ± 39.91	0.982
GGT (U/L)	38.00 (23.80-69.03)	69.70 (39.00-85.50)	0.023
ALT (U/L)	46.00 (30.33-64.95)	71.40 (46.9-111.70)	0.006
TC (mmol/L)	5.03 ± 1.04	4.76 ± 0.72	0.801
TG (mmol/L)	1.91 ± 0.74	2.04 ± 1.48	0.532
HDL-C (mmol/L)	1.21 ± 0.28	1.19 ± 0.28	0.903
LDL-C (mmol/L)	2.97 ± 0.91	2.72 ± 0.49	0.444
FBG (mmol/L)	6.43 ± 3.59	5.62 ± 1.77	0.318
UA (μmol/L)	360.91 ± 107.80	361.62 ± 106.22	0.482
CAP (dB/m)	295.50 (249.25-345.00)	333.00 (296.25-356.25)	0.038
LSM (kPa)	6.20 (4.55-9.95)	9.60 (6.50-12.85)	0.008
Obesity, n (%)	16 (72.73)	25 (60.97)	0.677
Hypertension, n (%)	8 (36.36)	14 (37.84)	0.910
T2DM, n (%)	3 (13.64)	4 (10.81)	0.746

The data are expressed as mean ± SD, or as n (%) for normally distributed variables and as median (interquartile range) when distribution of the variable was skewed. NAFL: Nonalcoholic fatty liver; NASH: Nonalcoholic steatohepatitis; BMI: Body mass index; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; ALT: Alanine aminotransferase; TC: Total cholesterol; TG: Triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; FBG: Fasting blood glucose; UA: Uric acid; LSM: Liver stiffness measurement; CAP: Controlled attenuation parameter; T2DM: Type 2 diabetes mellitus.

Table 3 Genotype distribution of PPARGC1A rs8192678 and patatin-like phospholipase domain-containing protein 3 rs738409 in patients with nonalcoholic fatty liver disease and controls

Genotype	NAFLD (n = 59)	Controls (n = 93)	χ²	P value	OR (95%CI)
PPARGC1A rs8192678
GG	14 (23.73%)	39 (41.94%)
GA	37 (62.71%)	37 (39.78%)	7.148	0.008	2.786 (1.300-5.962)
AA	8 (13.56%)	17 (18.28%)	0.262	0.609	1.311 (0.464-3.704)
GA+AA	45 (76.27%)	54 (58.06%)	5.269	0.022	2.321 (1.121-4.806)
PNPLA3 rs738409
CC	12 (20.34%)	35 (37.63%)
CG	27 (45.76%)	43 (46.24%)	2.152	0.142	1.831 (0.812-4.131)
GG	20 (33.90%)	15 (16.13%)	8.423	0.004	3.889 (1.524-9.926)
CG + GG	47 (79.56%)	58 (62.37%)	5.055	0.025	2.364 (1.105-5.055)

OR: Odds ratio; CI: Confidence interval; PNPLA3: Patatin-like phospholipase domain-containing protein 3; NAFLD: Nonalcoholic fatty liver disease.

Table 4 Association tests of PPARGC1A rs8192678 polymorphism between different groups

PPARGC1A rs8192678	Case			Control			Dominant model
PPARGC1A rs8192678	GG	GA	AA	GG	GA	AA	χ²	P value	OR (95%CI)
NAFLD vs Control	14	37	8	39	37	17	5.269	0.022	2.321 (1.121-4.806)
NASH vs Control	5	28	4	39	37	17	9.550	0.002	4.622 (1.653-12.929)
NASH vs NAFL	5	28	4	9	9	4	5.721	0.017	4.431 (1.245-15.763)
Obese vs nonobese participants	17	33	10	36	41	15	1.864	0.172	1.626 (0.807-3.276)
Obese NAFLD vs nonobese NAFLD	9	27	5	5	10	3	0.235	0.628	1.368 (0.384-4.865)
Obese NASH vs nonobese NASH	4	19	2	1	9	2	0.408	0.348	0.477 (0.047-4.806)
Obese NAFL vs nonobese NAFL	5	8	3	4	1	1	2.264	0.132	4.400 (0.596-32.501)
Obese NASH vs obese NAFL	4	19	2	5	8	3	1.324	0.250	2.386 (0.531-10.734)
Nonobese NASH vs nonobese NAFL	1	9	2	4	1	1	6.785	0.021	22.000 (1.540-314.292)

NAFL: Nonalcoholic fatty liver; NASH: Nonalcoholic steatohepatitis; NAFLD: Nonalcoholic fatty liver disease; OR: Odds ratio; CI: Confidence interval.

Table 5 Multiple logistic regression analysis of predictive factors for nonalcoholic fatty liver disease

Variables	B	S.E.	Wald	OR (95%CI)	P value
Age (year)	-0.031	0.015	4.236	0.970 (0.942-0.999)	0.040
Sex (Male)	-0.233	0.385	0.365	0.793 (0.373-1.686)	0.546
PPARGC1A rs8192678 A allele	0.789	0.388	4.148	2.202 (1.030-4.705)	0.042
PNPLA3 rs738409 G allele	0.857	0.403	4.524	2.356 (1.070-5.191)	0.033

OR: Odds ratio; CI: Confidence interval; PNPLA3: Patatin-like phospholipase domain-containing protein 3.

Table 6 Association of the PPARGC1A genotypes with steatosis, activity, and fibrosis in patients with nonalcoholic fatty liver disease

Histological features		Genotypes		Dominant model		Multivariate analysis¹
Histological features		GG (n = 14)	GA + AA (n = 45)	P value	OR (95%CI)	P value	OR (95%CI)
Steatosis (S)	S1	10 (71.43%)	15 (33.33%)
Steatosis (S)	S2-3	4 (28.57%)	30 (66.67%)	0.012	5.000 (1.343-18.620)	0.011	6.190 (1.508-25.410)
Activity (A)	A < 2	6 (42.86%)	7 (15.56%)
Activity (A)	A ≥ 2	8 (57.14%)	38 (84.44%)	0.031	4.071 (1.076-15.402)	0.040	4.506 (1.070-18.978)
Significant fibrosis	F0-1	12 (85.71%)	28 (62.22%)
Significant fibrosis	F2-4	2 (14.29%)	17 (37.78%)	0.100	3.643 (0.726-18.292)	0.186	3.449 (0.551-21.598)
Advanced fibrosis	F0-2	13 (92.86%)	35 (77.78%)
Advanced fibrosis	F3-4	1 (7.14%)	10 (22.22%)	0.206	3.714 (0.432-31.949)	0.426	2.549 (0.255-25.490)
NASH	NAFL	9 (64.28%)	13 (28.89%)
NASH	NASH	5 (35.71%)	32 (71.11%)	0.017	4.431 (1.245-15.763)	0.035	6.337 (1.135-35.392)

¹Multivariate analysis adjusted for age, sex, body mass index, and patatin-like phospholipase domain-containing protein 3 rs738409 risk G allele. NAFL: Nonalcoholic fatty liver; NASH: Nonalcoholic steatohepatitis; OR: Odds ratio; CI: Confidence interval.

Table 7 Biochemical and genetic characteristics of patients with nonobese nonalcoholic fatty liver disease

Variables	NAFL (n = 6)	NASH (n = 12)	P value
Sex (M/F)	4/2	10/2	0.569
Age (year)	35.33 ± 18.44	39.67 ± 4.80	0.452
BMI (kg/m²)	22.83 ± 1.61	23.69 ± 0.90	0.122
ALP (U/L)	123.32 ± 77.62	84.25 ± 23.28	0.426
GGT (U/L)	28.50 (21.18-85.00)	73.25 (54.75-99.25)	0.068
ALT (U/L)	42.00 (21.78-78.50)	71.15 (41.10-115.25)	0.325
TC (mmol/L)	5.11 ± 0.55	4.96 ± 1.02	0.606
TG (mmol/L)	2.00 ± 0.43	1.77 ± 0.95	0.371
HDL-C (mmol/L)	1.10 ± 0.16	1.24 ± 0.44	0.943
LDL-C (mmol/L)	3.16 ± 0.46	2.82 ± 0.80	0.524
FBG (mmol/L)	5.03 ± 0.94	5.24 ± 0.85	0.587
UA (μmol/L)	360.86 ± 167.34	354.17 ± 67.43	0.684
CAP (dB/m)	257.00 ± 57.03	316.73 ± 43.48	0.056
LSM (kPa)	6.95 ± 4.07	6.79 ± 2.06	0.421
PPARGC1A rs8162678
GG, n (%)	4 (66.67)	1 (8.33)
GA + AA, n (%)	2 (33.33)	11 (91.67)	0.021
PNPLA3 rs738409
CC, n (%)	2 (33.33)	1 (8.33)
CG + GG, n (%)	4 (66.67)	11 (91.67)	0.245

The data are expressed as mean ± SD, or as n (%) for normally distributed variables and as median (interquartile range) when distribution of the variable was skewed. NAFL: Nonalcoholic fatty liver; NASH: Nonalcoholic steatohepatitis; BMI: Body mass index; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; TC: Total cholesterol; TG: Total triglycerides; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; FBG: Fasting blood glucose; UA: Uric acid; LSM: Liver stiffness measurement; CAP: Controlled attenuation parameter; PNPLA3: Patatin-like phospholipase domain-containing protein 3.

Citation: Zhang RN, Shen F, Pan Q, Cao HX, Chen GY, Fan JG. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease . World J Gastroenterol 2021; 27(25): 3863-3876
URL: https://www.wjgnet.com/1007-9327/full/v27/i25/3863.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i25.3863